 Hello, my name is Alex Goldberg and I'm a research fellow at the Center for Engineering and Medicine in Massachusetts General Hospital. Our long term goal is to identify mechanisms of hypertrophic scar formation and to develop new multi-target therapies to prevent scarring. Hypertrophic scar is a common clinical condition with no effective therapy. Despite a broad body of available scientific literature, underlying mechanisms of pathotheseological formation of scars are fully understood. Delays in fibroblast apoptosis are thought to be one of the reasons for hypertrophic scarring. In this work, we introduce a new chemical free method for fibroblast cell density control and culture by intermediate delivery of pulsobacteric pills, which cause irreversible damage to cell membrane by a process called non-thermal irreversible electroporation. Thus, we investigated the effects of pulsoleptic fluid application of growth, death, and regeneration of normal human dermal fibroblasts and culture. We found that the fraction of fibroblasts that survive depends on the number of pulsozaplied and pulsovailable distribution function. Next, we have successfully developed an intermediate-delivered pulsoleptic fluid protocol that controls fibroblast density and culture. Through application of pulsoleptic fluid intermittently, every 72 hours for 12 days, we maintained a normal dermal fibroblast density at the 43-100% confluence range. Our results suggest that intermediate-delivered pulsoleptic fields may be used as a non-chemical method for fibroblast density control in human wound healing.